Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study
Michael W Fried, Maria Buti, Gregory J Dore, Robert Flisiak, Peter Ferenci, Ira Jacobson, Patrick Marcellin, Michael Manns, Igor Nikitin, Fred Poordad, Morris Sherman, Stefan Zeuzem, Jane Scott, Leen Gilles, Oliver Lenz, Monika Peeters, Vanitha Sekar, Goedele De Smedt, Maria Beumont-Mauviel, Michael W Fried, Maria Buti, Gregory J Dore, Robert Flisiak, Peter Ferenci, Ira Jacobson, Patrick Marcellin, Michael Manns, Igor Nikitin, Fred Poordad, Morris Sherman, Stefan Zeuzem, Jane Scott, Leen Gilles, Oliver Lenz, Monika Peeters, Vanitha Sekar, Goedele De Smedt, Maria Beumont-Mauviel
Abstract
The phase IIb, double-blind, placebo-controlled PILLAR trial investigated the efficacy and safety of two different simeprevir (SMV) doses administered once-daily (QD) with pegylated interferon (Peg-IFN)-α-2a and ribavirin (RBV) in treatment-naïve patients with HCV genotype 1 infection. Patients were randomized to one of five treatments: SMV (75 or 150 mg QD) for 12 or 24 weeks or placebo, plus Peg-IFN and RBV. Patients in the SMV arms stopped all treatment at week 24 if response-guided therapy (RGT) criteria were met; patients not meeting RGT continued with Peg-IFN and RBV until week 48, as did patients in the placebo control group. Sustained virologic response (SVR) rates measured 24 weeks after the planned end of treatment (SVR24) were 74.7%-86.1% in the SMV groups versus 64.9% in the control group (P < 0.05 for all comparisons [SMV versus placebo], except SMV 75 mg for 24 weeks). Rapid virologic response (HCV RNA <25 IU/mL undetectable at week 4) was achieved by 68.0%-75.6% of SMV-treated and 5.2% of placebo control patients. According to RGT criteria, 79.2%-86.1% of SMV-treated patients completed treatment by week 24; 85.2%-95.6% of these subsequently achieved SVR24. The adverse event profile was generally similar across the SMV and placebo control groups, with the exception of mild reversible hyperbilirubinemia, without serum aminotransferase abnormalities, associated with higher doses of SMV.
Conclusion: SMV QD in combination with Peg-IFN and RBV significantly improves SVR rates, compared with Peg-IFN and RBV alone, and allows the majority of patients to shorten their therapy duration to 24 weeks.
Trial registration: ClinicalTrials.gov NCT00882908.
© 2013 by the American Association for the Study of Liver Diseases.
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4112500/bin/nihms576416f1.jpg)
![Fig. 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4112500/bin/nihms576416f2.jpg)
Fig. 3
Difference in SVR24 between SMV…
Fig. 3
Difference in SVR24 between SMV 150 mg and placebo groups by demographic parameters.…
Fig. 4
Change in bilirubin and ALT…
Fig. 4
Change in bilirubin and ALT concentration up to week 72. ALT, alanine aminotransferase;…
Fig. 5
Change from baseline in total…
Fig. 5
Change from baseline in total FSS score up to week 72. FSS, Fatigue…
- Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, Janczewska E, Villamil F, Scott J, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M. Manns M, et al. Lancet. 2014 Aug 2;384(9941):414-26. doi: 10.1016/S0140-6736(14)60538-9. Epub 2014 Jun 4. Lancet. 2014. PMID: 24907224 Clinical Trial.
- Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study.Hayashi N, Seto C, Kato M, Komada Y, Goto S. Hayashi N, et al. J Gastroenterol. 2014 Jan;49(1):138-47. doi: 10.1007/s00535-013-0875-1. Epub 2013 Sep 5. J Gastroenterol. 2014. PMID: 24005956 Free PMC article. Clinical Trial.
- Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, Moroz L, Craxi A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Scott J, Sinha R, Beumont-Mauviel M. Jacobson IM, et al. Lancet. 2014 Aug 2;384(9941):403-13. doi: 10.1016/S0140-6736(14)60494-3. Epub 2014 Jun 4. Lancet. 2014. PMID: 24907225 Clinical Trial.
- Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial.Hayashi N, Izumi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Ki R, Komada Y, Seto C, Goto S. Hayashi N, et al. J Hepatol. 2014 Aug;61(2):219-27. doi: 10.1016/j.jhep.2014.04.004. Epub 2014 Apr 12. J Hepatol. 2014. PMID: 24727123 Clinical Trial.
- Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.Manns MP, Markova AA, Calle Serrano B, Cornberg M. Manns MP, et al. Liver Int. 2012 Feb;32 Suppl 1:27-31. doi: 10.1111/j.1478-3231.2011.02725.x. Liver Int. 2012. PMID: 22212568 Review.
- Evolution of care in cirrhosis: Preventing hepatic decompensation through pharmacotherapy.Lee S, Saffo S. Lee S, et al. World J Gastroenterol. 2023 Jan 7;29(1):61-74. doi: 10.3748/wjg.v29.i1.61. World J Gastroenterol. 2023. PMID: 36683719 Free PMC article. Review.
- Antibody-Mediated Rejection and Recurrent Primary Disease: Two Main Obstacles in Abdominal Kidney, Liver, and Pancreas Transplants.Nakamura T, Shirouzu T. Nakamura T, et al. J Clin Med. 2021 Nov 19;10(22):5417. doi: 10.3390/jcm10225417. J Clin Med. 2021. PMID: 34830699 Free PMC article. Review.
- Viral hepatitis: Milestones, unresolved issues, and future goals.Torre P, Aglitti A, Masarone M, Persico M. Torre P, et al. World J Gastroenterol. 2021 Jul 28;27(28):4603-4638. doi: 10.3748/wjg.v27.i28.4603. World J Gastroenterol. 2021. PMID: 34366625 Free PMC article. Review.
- Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches.Bhowmik D, Nandi R, Jagadeesan R, Kumar N, Prakash A, Kumar D. Bhowmik D, et al. Infect Genet Evol. 2020 Oct;84:104451. doi: 10.1016/j.meegid.2020.104451. Epub 2020 Jul 5. Infect Genet Evol. 2020. PMID: 32640381 Free PMC article.
- New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials.Pecoraro V, Banzi R, Cariani E, Chester J, Villa E, D'Amico R, Bertele' V, Trenti T. Pecoraro V, et al. J Clin Exp Hepatol. 2019 Jul-Aug;9(4):522-538. doi: 10.1016/j.jceh.2018.07.004. Epub 2018 Jul 19. J Clin Exp Hepatol. 2019. PMID: 31516269 Free PMC article. Review.
- Clinical Trial, Phase II
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
- Adolescent
- Adult
- Aged
- Female
- Hepacivirus / genetics
- Hepatitis C, Chronic / drug therapy*
- Heterocyclic Compounds, 3-Ring / administration & dosage*
- Heterocyclic Compounds, 3-Ring / adverse effects
- Humans
- Interferon-alpha / administration & dosage*
- Interferon-alpha / adverse effects
- Male
- Middle Aged
- Polyethylene Glycols / administration & dosage*
- Polyethylene Glycols / adverse effects
- RNA, Viral / blood
- Recombinant Proteins / administration & dosage
- Recombinant Proteins / adverse effects
- Ribavirin / administration & dosage*
- Ribavirin / adverse effects
- Simeprevir
- Sulfonamides / administration & dosage*
- Sulfonamides / adverse effects
- Treatment Outcome
- Viral Load / drug effects
- Heterocyclic Compounds, 3-Ring
- Interferon-alpha
- RNA, Viral
- Recombinant Proteins
- Sulfonamides
- Polyethylene Glycols
- Ribavirin
- Simeprevir
- peginterferon alfa-2a
- ClinicalTrials.gov/NCT00882908
- Full Text Sources
- Other Literature Sources
- Medical
- Miscellaneous
![Fig. 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4112500/bin/nihms576416f3.jpg)
Fig. 4
Change in bilirubin and ALT…
Fig. 4
Change in bilirubin and ALT concentration up to week 72. ALT, alanine aminotransferase;…
Fig. 5
Change from baseline in total…
Fig. 5
Change from baseline in total FSS score up to week 72. FSS, Fatigue…
![Fig. 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4112500/bin/nihms576416f4.jpg)
![Fig. 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4112500/bin/nihms576416f5.jpg)
Source: PubMed